# Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct05019690/  
OnCo record `nct05019690` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of rivoceranib (apatinib) and nab-paclitaxel in triple-negative breast cancer, run by Fujian Cancer Hospital, now recruiting.

## Summary

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer is a phase 1/2, interventional study registered as NCT05019690 by Fujian Cancer Hospital, with a registry enrolment figure of 29 participants, started 2021-10-01 and due to reach its primary completion in 2024-12-01. Interventions recorded: Apatinib Mesylate; Albumin-Bound Paclitaxel. Conditions listed: Advanced Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically or pathologically confirmed advanced triple-negative breast cancer that meets the following criteria:". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05019690
- Phase: 1/2
- Setting: Apatinib Mesylate Combined with Albumin-bound Paclitaxel for Second-line Treatment of Advanced Triple Negative Breast Cancer:a Single-arm,exploratory Clinical Study
- Sponsor: Fujian Cancer Hospital
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT05019690: https://clinicaltrials.gov/study/NCT05019690

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Rivoceranib (apatinib)](https://onco.cc/drugs/rivoceranib/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05019690.json